Ginkgo Bioworks: what a $15B SPAC looks like five years later

The original problem. Ginkgo's pitch, from MIT synthetic-biology researchers led by Jason Kelly and Tom Knight (founded 2008), was that organism engineering should become an industrial platform: a "foundry" with massive automation and scale economics that would make designing a microbe dramatically cheaper, with Ginkgo taking cash plus equity/royalties in the customers' products.

Why the model was attractive and why it was fragile. The platform argument depends on a learning curve — each program makes the next cheaper. The fragility is that the customers were mostly other venture-funded biotech startups, which meant Ginkgo's revenue was a derivative of biotech venture funding. When that funding contracted in 2022–2023, so did Ginkgo's order book.

Funding and the SPAC. Ginkgo raised over $800M privately, then went public via SPAC (Soaring Eagle Acquisition Corp) in September 2021 at roughly a $15 billion valuation — one of the largest de-SPACs ever. COVID testing (Concentric) provided a large, temporary revenue spike that flattered the numbers going in.

The short-seller report. In October 2021, Scorpion Capital published a report alleging that a large share of Ginkgo's revenue came from related parties — companies Ginkgo itself had founded or held equity in — and that the foundry economics were overstated. Ginkgo rejected the allegations. Regardless of the report's merits, the related-party revenue concentration was disclosed and real, and the market subsequently discounted it.

Current status (September 2026) — the numbers. Q2 2026 revenue of $20 million, down 48% from $39 million a year earlier, attributed to "program rationalization" after restructuring; net loss from continuing operations of $57 million; adjusted EBITDA of -$36 million; $302 million in cash and marketable securities; reaffirmed full-year cash burn guidance of $125–150 million (Ginkgo Bioworks 8-K, Q2 2026) [Verified — SEC filing]. The company executed a 1-for-40 reverse stock split to maintain listing compliance (GenomeWeb).

It is pivoting toward selling automation itself — a $47M contract to build a 97-instrument autonomous lab for Pacific Northwest National Laboratory, similar projects at Caltech, Northwestern and Maryland, and a cheaper pharma ADME service that signed 17 customers in six weeks. That is a real business. It is also a fundamentally different and much smaller one than the platform story the SPAC was sold on.

Lessons that generalize.

1. Going public before the business model is proven transfers the risk to public shareholders and removes your ability to pivot quietly. Every subsequent strategic change happens under quarterly scrutiny.
2. Check whose money your revenue is ultimately coming from. If your customers are all venture-funded, your revenue is a leveraged bet on the venture cycle.

---